Why the study?
Does the thromboxane antagonist Bay u 3405 inhibit platelet aggregation and enhance the antiplatelet effects of aspirin in an in vitro human blood perfusion system?
Population
Human blood in an in vitro perfusion system exposing vascular subendothelium to circulating blood
Comparison
Bay u 3405 in vitro, alone or added to blood… vs Control and Aspirin 500 mg/day in vivo
Design
Preclinical
Authors
Loading...
May enhance aspirin's effects in vitro; hypothesis-generating and should not change practice.
Does the thromboxane antagonist Bay u 3405 inhibit platelet aggregation and enhance the antiplatelet effects of aspirin in an in vitro human blood perfusion system?
The thromboxane antagonist Bay u 3405 inhibits platelet aggregation in vitro and potentiates the antiplatelet effects of aspirin.
Escolar et al. (1998) studied this question.